# Basic Analysis of moderna

Moderna is a biotechnology company that specializes in the development of messenger RNA (mRNA) therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna is a publicly traded company on the NASDAQ stock exchange and has a market capitalization of over $30 billion.  
  
Moderna’s mission is to develop and deliver mRNA-based medicines and vaccines that improve the lives of patients around the world. The company has developed a platform that enables the design and development of mRNA-based medicines and vaccines to treat a wide range of diseases. Moderna has a portfolio of over 20 mRNA-based medicines and vaccines in clinical development, including a vaccine for COVID-19.  
  
Moderna’s financial performance has been strong in recent years. In 2020, the company reported total revenue of $1.7 billion, up from $579 million in 2019. This growth was primarily driven by the sale of its COVID-19 vaccine, which generated $1.6 billion in revenue. Moderna’s net income for 2020 was $1.1 billion, up from $7 million in 2019.  
  
Moderna’s corporate structure consists of a Board of Directors, an Executive Team, and a Scientific Advisory Board. The Board of Directors is responsible for overseeing the company’s strategic direction and ensuring that the company is meeting its financial and operational goals. The Executive Team is responsible for the day-to-day operations of the company, including research and development, manufacturing, and commercialization. The Scientific Advisory Board is composed of leading scientists and clinicians who provide guidance on the development of Moderna’s mRNA-based medicines and vaccines.  
  
Moderna has a strong presence in the biotechnology industry and is well-positioned for future growth. The company has a portfolio of mRNA-based medicines and vaccines in clinical development, and its COVID-19 vaccine has been approved for use in several countries. In addition, Moderna has a strong financial position, with total revenue of $1.7 billion in 2020 and a net income of $1.1 billion. The company is well-positioned to continue to develop and deliver mRNA-based medicines and vaccines that improve the lives of patients around the world.